Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013)
Bio-Techne (TECH) posted quarterly Curent Deferred Tax Liability of $9.9 million for Q2 2013, down 30.14% year-over-year from $14.2 million in Q2 2012, and down 1.23% quarter-over-quarter from $10.1 million in Q1 2013.
Powered by 
Analysis
Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013) Analysis & Trends
Bio-Techne's Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $9.9 million for Q2 2013.
- In Q2 2013, Curent Deferred Tax Liability fell 30.14% year-over-year to $9.9 million; the TTM figure through Jun 2013 stood at $9.9 million (down 30.14% YoY), while the FY2013 annual figure was $9.9 million, down 30.14% from the prior year.
- Curent Deferred Tax Liability for Q2 2013 stood at $9.9 million, down from $10.1 million in the prior quarter.
- The five-year high for Curent Deferred Tax Liability was $14.2 million in Q2 2012, with the low at $4.2 million in Q4 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2013 | 9.94 Mn |
| Mar 31, 2013 | 10.07 Mn |
| Dec 31, 2012 | 4.21 Mn |
| Sep 30, 2012 | 6.17 Mn |
| Jun 30, 2012 | 14.23 Mn |
| Mar 31, 2012 | 4.26 Mn |